+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Biopsy Market, by Cancer Segment, Volume of Biopsy and Patient Diagnosed Numbers, Company Analysis

  • ID: 5115527
  • Report
  • June 2020
  • Region: China
  • 200 Pages
  • Renub Research

FEATURED COMPANIES

  • C. R. Bard Inc.
  • Cardinal Health Inc
  • Hologic Inc.
Cancer is the leading cause of mortality in China. There approximately 4.3 Million cancer cases and 2.9 Million cancer death occurred over in 2018. So an average of 7 people was diagnosed with cancer, while 4 people died of cancer every minute in China. China has 40% higher motility rate compared to the United Kingdom and the United States. Imaging tests like X-rays and CT scans assist in discovering areas of concerns, but they can’t differentiate between cancerous and noncancerous cells. For the diagnosis of cancer, a biopsy is the only sure way to identify most cancers. According to this report, China Biopsy Market is expected to reach USD 8.1 Billion by the end of the year 2026.

How COVID-19 affects China Biopsy Industry

The Coronavirus outbreak has come as a massive blow on the biopsy diagnostics centres, hospitals, supply chain and clinical trials of the biopsy industry. As per our findings, the biopsy market in China got affected a bit from December 2019 to April 2020. Read the complete analysis of COVID-19 in our report. As for how this pandemic is affecting the biopsy industry in China and when it’s going to revive.

Reasons for Growth in Cancer Cases and High Mortality Rate in China

The rise in cancer cases has been driven by an ageing population and the prevalence of lifestyle factors such as smoking, stress and sedentary lifestyle.

The prime reasons for the higher mortality in China are due to its low rate of early-stage cancers detection, and another reason is that China still has non-uniformed clinical cancer treatment strategies performed by different regions.

Top 3 Types of Cancers in China

Chinese population is mostly affected by three types of cancer Breast Cancer, Liver cancer, Colon and Rectum cancer. Breast cancer is one of the most common cancer among women in China. Our study also reveals that breast cancer rates are higher in urban areas of China than in rural areas. As with the rapid development of China’s economy, more and more people have moved from rural areas to large cities.

This is a known fact that having more than one child lowers breast-cancer risk. But China had 1 child policy from 1979, and since most of the women work in the city, they have to follow the policy to avoid penalty. Although this one-child rule was repealed in 2015 with two-child policy rule, however, it will take 15 to 20 years for this policy to show any result.

This report titled “China Biopsy Market, by Cancer Segment (Breast cancer, prostate cancer, lung cancer, liver cancer, thyroid cancer, kidney cancer, colon & rectum cancer, kidney cancer, leukemia, pancreas cancer, and bladder cancer), Volume of Biopsy and Patient Diagnosed Numbers, Company (C. R. Bard, Inc., Becton, Dickinson and Company, Cardinal Health, Inc, Boston Scientific Corporation and Hologic, Inc.)” provides an all-encompassing analysis on the Biopsy Market in China.

10 cancer segments have been studied in this report, and each cancer segment is covered from 3 points

1. Market
2. Volume of Biopsy
3. Patient Diagnosed

Cancer Segments covered in the report

1. Breast Cancer
2. Prostate Cancer
3. Lung Cancer
4. Liver Cancer
5. Thyroid Cancer
6. Colon & Rectum Cancer
7. Kidney Cancer
8. Leukaemia
9. Pancreas Cancer
10. Bladder Cancer

All the companies have been studied from three points
  • Overview
  • Recent Developments
  • Sales Analysis

Company Analysis
  • C. R. Bard, Inc.
  • Becton, Dickinson and Company
  • Cardinal Health, Inc
  • Boston Scientific Corporation
  • Hologic, Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • C. R. Bard Inc.
  • Cardinal Health Inc
  • Hologic Inc.

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Market & Volume Analysis - China Biopsy Test
5.1 Market
5.2 Volume
6. Market & Volume Share - China Biopsy Test
6.1 Market Share
6.2 Volume Share
7. Segment Analysis - China Biopsy Test Market
7.1 Breast Cancer
7.1.1 Market
7.1.2 Volume of Biopsy
7.1.3 Patient Diagnosed Numbers
7.2 Prostate Cancer
7.2.1 Market
7.2.2 Volume of Biopsy
7.2.3 Patient Diagnosed Numbers
7.3 Lung Cancer
7.3.1 Market
7.3.2 Volume of Biopsy
7.3.3 Patient Diagnosed Numbers
7.4 Liver Cancer
7.4.1 Market
7.4.2 Volume of Biopsy
7.4.3 Patient Diagnosed Numbers
7.5 Thyroid Cancer
7.5.1 Market
7.5.2 Volume of Biopsy
7.5.3 Patient Diagnosed Numbers
7.6 Colon & Rectum Cancer
7.6.1 Market
7.6.2 Volume of Biopsy
7.6.3 Patient Diagnosed Numbers
7.7 Kidney Cancer
7.7.1 Market
7.7.2 Volume of Biopsy
7.7.3 Patient Diagnosed Numbers
7.8 Leukaemia
7.8.1 Market
7.8.2 Volume of Biopsy
7.8.3 Patient Diagnosed Numbers
7.9 Pancreas Cancer
7.9.1 Market
7.9.2 Volume of Biopsy
7.9.3 Patient Diagnosed Numbers
7.10 Bladder Cancer
7.10.1 Market
7.10.2 Volume of Biopsy
7.10.3 Patient Diagnosed Numbers
8. Merger & Acquisition
9. Company Analysis
9.1 C. R. Bard, Inc.
9.1.1 Overview
9.1.2 Initiatives/Recent Developments
9.1.3 Financial Insight
9.2 Becton, Dickinson and Company
9.2.1 Overview
9.2.2 Initiatives/Recent Developments
9.2.3 Financial Insight
9.3 Cardinal Health, Inc.
9.3.1 Overview
9.3.2 Initiatives/Recent Developments
9.3.3 Financial Insight
9.4 Boston Scientific Corporation
9.4.1 Overview
9.4.2 Initiatives/Recent Developments
9.4.3 Financial Insight
9.5 Hologic, Inc.
9.5.1 Overview
9.5.2 Initiatives/Recent Developments
9.5.3 Financial Insight
List of Figures:
Figure 1: China - Biopsy Market (Million US$), 2015 - 2019
Figure 2: China - Forecast for Biopsy Market (Million US$), 2020 - 2026
Figure 3: China - Biopsy Market Volume (In Number), 2015 - 2019
Figure 4: China - Forecast For Biopsy Market Volume (In Number), 2020 - 2026
Figure 5: China - Breast Cancer Biopsy Market, (Million US$), 2015 - 2019
Figure 6: China - Forecast For Breast Cancer Biopsy Market, (Million US$), 2020 - 2026
Figure 7: China - Breast Cancer Diagnosed (In Numbers), 2015 - 2019
Figure 8: China - Forecast For Breast Cancer Diagnosed (In Number), 2020 - 2026
Figure 9: China - Breast Cancer Biopsy (In Number), 2015 - 2019
Figure 10: China - Forecast For Breast Cancer Biopsy (In Number), 2020 - 2026
Figure 11: China - Prostate Cancer Biopsy Market, (Million US$), 2015 - 2019
Figure 12: China - Prostate Cancer Biopsy Market Forecast, (Million US$), 2020 - 2026
Figure 13: China - Prostate Cancer Diagnosed (In Numbers), 2015 - 2019
Figure 14: China - Forecast For Prostate Cancer Diagnosed (In Number), 2020 - 2026
Figure 15: China - Prostate Cancer Biopsy (In Number), 2015 - 2019
Figure 16: China - Forecast For Prostate Cancer Biopsy (In Number), 2020 - 2026
Figure 17: China - Lung Cancer Biopsy Market, (Million US$), 2015 - 2019
Figure 18: China - Lung Cancer Biopsy Forecast Market, (Million US$), 2020 - 2026
Figure 19: China - Lung Cancer Diagnosed (In Number), 2015 - 2019
Figure 20: China - Forecast For Lung Cancer Diagnosed (In Number), 2020 - 2026
Figure 21: China - Lung Cancer Biopsy (In Number), 2015 - 2019
Figure 22: China - Forecast For Lung Cancer Biopsy (In Number), 2020 - 2026
Figure 23: China - Liver Cancer Biopsy Market (Million US$), 2015 - 2019
Figure 24: China - Forecast For Liver Cancer Biopsy Market (Million US$), 2020 - 2026
Figure 25: China - Liver Cancer Diagnosed (In Number), 2015 - 2019
Figure 26: China - Forecast For Liver Cancer, 2020 - 2026
Figure 27: China - Liver Cancer Diagnosed (In Number), 2015 - 2019
Figure 28: China - Forecast For Liver Cancer Diagnosed (In Number), 2020 - 2026
Figure 29: China - Thyroid Cancer Biopsy Market, (Million US$), 2015 - 2019
Figure 30: China - Forecast Thyroid Cancer Biopsy Market, (Million US$), 2020 - 2026
Figure 31: China - Thyroid Cancer Diagnosis (In Number), 2012 - 2019
Figure 32: China - Forecast For Thyroid Cancer Diagnosis (In Number), 2020 - 2026
Figure 33: China - Thyroid Cancer Biopsy (In Number), 2015 - 2019
Figure 34: China - Forecast For Thyroid Cancer Biopsy (In Number), 2020 - 2026
Figure 35: China - Colon & Rectum Cancer Biopsy Market, (Million US$), 2015 - 2019
Figure 36: China - Forecast For Colon & Rectum Cancer Biopsy Market, (Million US$), 2020 - 2026
Figure 37: China - Colon & Rectum Cancer Diagnosed (In Number), 2015 - 2019
Figure 38: China - Forecast For Colon & Rectum Cancer Diagnosed (In Number), 2020 - 2026
Figure 39: China - Colon & Rectum Cancer Biopsy (In Number), 2015 - 2019
Figure 40: China - Forecast For Colon & Rectum Cancer Biopsy (In Number), 2020 - 2026
Figure 41: China - Kidney Cancer Biopsy Market, (Million US$), 2015 - 2019
Figure 42: China - Kidney Cancer Biopsy Market Forecast, (Million US$), 2020 - 2026
Figure 43: China - Kidney Cancer Diagnosed, 2015 - 2019
Figure 44: China - Kidney Cancer Diagnosed Forecast, 2020 - 2026
Figure 45: China - Kidney Cancer Biopsy (In Number), 2015 - 2019
Figure 46: China - Forecast for Kidney Cancer Biopsy (In Number), 2020 - 2025
Figure 47: China - Leukemia Cancer Biopsy Market (Million US$), 2015 - 2019
Figure 48: China - Forecast For Leukemia Cancer Biopsy Market (Million US$), 2020 - 2026
Figure 49: China - Leukemia Cancer Diagnosed ( In Number), 2015 - 2019
Figure 50: China - Forecast For Leukemia Cancer Diagnosed (In Number), 2020 - 2026
Figure 51: China - Leukemia Cancer Biopsy (In Number), 2015 - 2019
Figure 52: China - Forecast For Leukemia Cancer Biopsy (In Number), 2020 - 2026
Figure 53: China - Pancreas Cancer Biopsy Market,(Million US$), 2015 - 2019
Figure 54: China - Forecast For Pancreas Cancer Biopsy Market,(Million US$), 2020 - 2026
Figure 55: China - Pancreas Cancer Diagnosed, 2015 - 2019
Figure 56: China - Pancreas Cancer Diagnosed Forecast, 2020-2026
Figure 57: China - Pancreas Cancer Biopsy (In Number), 2015 - 2019
Figure 58: China - Forecast For Pancreas Cancer Biopsy (In Number) 2020 - 2026
Figure 59: China - Bladder Cancer Biopsy Market, 2015 - 2019
Figure 60: China - Bladder Cancer Biopsy Market Forecast, 2020 - 2026
Figure 61: China - Bladder Cancer Diagnosed (In Number), 2015 - 2019
Figure 62: China - Forecast For Bladder Cancer Diagnosed (In Number), 2020 - 2026
Figure 63: China - Bladder Cancer Biopsy (In Number), 2015 - 2019
Figure 64: China - Forecast For Bladder Cancer Biopsy (In Number) 2020 - 2026
Figure 64: Revenue C. R. Bard, Inc (Million US$), 2014 - 2019
Figure 65: Revenue Forecast For C. R. Bard, Inc (Million US$), 2020 - 2026
Figure 66: Revenue Becton, Dickinson and Company (Million US$), 2014 - 2019
Figure 67: Forecast For Revenue Becton, Dickinson and Company (Million US$), 2020 - 2026
Figure 68: Revenue Cardinal Health Inc. (Billion US$), 2014 - 2019
Figure 69: Forecast For Revenue Cardinal Health, Inc (Billion US$), 2020 - 2026
Figure 70: Revenue Boston Scientific Corporation (Billion US$), 2014 - 2019
Figure 71: Revenue Forecast For Boston Scientific Corporation (Billion US$), 2020 - 2026
Figure 72: Revenue Hologic, Inc (Billion US$), 2014 - 2019
Figure 73: Revenue Forecast For Hologic, Inc (Billion US$), 2020 - 2026
List of Tables:
Table 1: China Biopsy Market Share, (Million US$), 2016 - 2019
Table 2: China Biopsy Market Share Forecast, (Million US$), (Million US$), 2020 - 2026
Table 3: China Biopsy Volume Share, (Million US$), (Million US$), 2015 - 2019
Table 4: China Biopsy Volume Share Forecast, (Million US$), (Million US$), 2020 - 2025
Note: Product cover images may vary from those shown
  • C. R. Bard Inc.
  • Becton Dickinson and Company
  • Cardinal Health Inc
  • Boston Scientific Corporation
  • Hologic Inc.
Note: Product cover images may vary from those shown

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...